NCT04064879View on ClinicalTrials.gov

The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine

NASuspendedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

August 15, 2023

Study Completion Date

August 16, 2023

Conditions
Chronic Migraine, Headache
Interventions
OTHER

AD-SVF

Intravenous, intra-articular, and soft tissue injection delivery of SVF. Target regions include forehead, temporal, and suboccipital regions.

Trial Locations (1)

90403

Neurological Associates of West Los Angeles, Santa Monica

Sponsors
All Listed Sponsors
collaborator

Cell Surgical Network Inc.

INDUSTRY

lead

Neurological Associates of West Los Angeles

OTHER